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A critical advance in the treatment of advanced non-small
cell lung cancer (NSCLC) over the last 20 years has been
thedevelopmentoftolerableplatinum-basedchemotherapy
doublets[1].Despitethis,theestimatedsurvivaltimeofpa-
tientsisstillonlyslightly12monthsinthebestlarge,ran-
domized clinical trials [2, 3], and only 6 months for the
general population with newly diagnosed advanced
NSCLC [4]. Interestingly, a recent analysis of the Surveil-
lance, Epidemiology, and End Results data from 1990–
2005 does demonstrate a significant but modest
improvement in the treatment of stage IV lung cancer over
the last 15 years, with 1-year survival rates improving by
6% and 2-year survival rates improving by 3%. Within this
recent analysis, it is clear that different histologic subtypes
of NSCLC have had differential improvements. Patients
with adenocarcinoma histology have seen an 8% improve-
mentintheir1-yearsurvivalrate,from15%to23%,evenin
an era before the clinical significance of histology was rec-
ognized. Much of this benefit was achieved during the
2002–2005 period, in which erlotinib, gefitinib, and pem-
etrexed were approved, and during that period the observed
survival duration for patients with the adenocarcinoma and
squamous cell histologic subtypes diverged for the first
time in history. With multiple new treatments that appear
safer and more effective in patients with adenocarcinoma,
this difference is likely to widen in the coming years. It is
clear that histology is critical in choosing the appropriate
therapyforNSCLCpatients.Inthiseditorial,specifictreat-
ment implications for each histological subtype are ad-
dressed.Goingforward,itislikelythatimprovedmolecular
testing will augment and even replace histologic classifica-
tion alone.
For patients with adenocarcinoma, treatment options
have grown dramatically over the last few years. First-line
treatment consists of four to six cycles of a platinum-con-
taining chemotherapy doublet, plus bevacizumab for eligi-
ble patients. The incorporation of pemetrexed into
bevacizumab-containing first-line regimens appears to be
safe and effective [5], and a randomized phase III compar-
ison of the benchmark regimen of carboplatin, paclitaxel,
and bevacizumab with carboplatin, pemetrexed, and bev-
acizumab is ongoing. For patients with adenocarcinoma
knowntohaveanepidermalgrowthfactorreceptor(EGFR)
mutation, first-line tyrosine kinase inhibitor therapy should
be considered based on the recent Iressa Pan-Asia Study
(IPASS), which demonstrated better progression-free sur-
vival and quality of life in patients with an EGFR mutation
treated with gefitinib as compared with chemotherapy [6].
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strongly predicts resistance to this therapy, and it should be
avoided in patients with known KRAS mutations [7, 8]. In
the second-line setting, an overall survival benefit favoring
both pemetrexed and erlotinib has been observed from the
strategy of “switch maintenance”: giving a noncrossresis-
tant therapy before symptomatic or radiographic progres-
sion [3, 9]. Based on these data, the U.S. Food and Drug
Administration (FDA) recently approved pemetrexed as
maintenance therapy for patients with locally advanced or
metastatic nonsquamous NSCLC whose disease has not
progressed after four cycles of platinum-based first-line
chemotherapy. This strategy is likely to be most beneficial
for individuals in whom symptomatic progression of dis-
ease may preclude later treatment, but does have the theo-
retical downside of depriving patients of a treatment-free
interval following first-line therapy.
Unfortunately, patients with squamous cell histology
have relatively fewer options outside the scope of a clinical
trial.Forthesepatients,platinum-baseddoubletchemother-
apyisstillthemainstayoftreatment.Althoughgemcitabine
plus cisplatin was compared directly with pemetrexed plus
cisplatin and appeared to have a more favorable response
rate in patients with squamous cell histology [10], all non-
pemetrexed containing chemotherapy doublets are proba-
bly similarly effective in squamous cell tumors. Regarding
the role of targeted therapy, the monoclonal EGFR anti-
body cetuximab has a survival benefit in combination with
cisplatin and vinorelbine, but not with carboplatin and pac-
litaxel [11, 12]. In the First-Line Trial for Patients with
EGFR-Expressing Advanced NSCLC (FLEX), this im-
provement in survival appeared to be driven in part by a
trend toward benefit in the 33% of enrolled patients with
squamoustumors(hazardratio[HR],0.80;95%confidence
interval [CI], 0.64–1.00), as compared with adenocarci-
noma patients, who have a smaller degree of benefit (HR,
0.95; 95% CI, 0.77–1.15). Therefore, a first-line regimen
with cetuximab may be considered for patients with squa-
mous cell histology. Following first-line treatment, the
strategy of switch maintenance to erlotinib also appears to
retain a progression-free survival benefit even in patients
with squamous histology, but whether this is also true of
overall survival has not yet been reported [9]. For second-
line treatment and beyond, many other chemotherapy agents,
except for pemetrexed, appear to have modest and equivalent
activity in NSCLC patients regardless of histology. Of these,
both erlotinib and docetaxel are FDA approved.
The diagnosis of bronchioloalveolar carcinoma (BAC),
a less invasive subtype of NSCLC adenocarcinoma charac-
terized by well-differentiated cells growing along pulmo-
nary septae, may also imply a particular treatment strategy.
This type of NSCLC may be enriched for mutations in the
EGFR tyrosine kinase domain, which are strongly associ-
atedwithresponsetoEGFRtyrosinekinaseinhibitor(TKI)
treatment. However, there is variability in histology and
molecular status even within this NSCLC subtype. In a se-
ries of 111 adenocarcinoma patients from our institution,
EGFR mutations were observed in 47% of patients with
nonmucinous BACs, but patients with the mucinous form
of BAC never had an EGFR mutation, and six of seven ac-
tually had a KRAS mutation [13]. These data suggest that
patients with nonmucinous BAC have a reasonable chance
of responding to “empiric” EGFR TKI therapy, but that
TKI treatment should probably be avoided in patients with
mucinous BAC unless the molecular status is known.
In summary, an increasing array of therapeutic options
Table 1. Table of NSCLC therapies associated with effectiveness in particular histologies
Therapy Histologic subtype Notes
Erlotinib, gefitinib Adenocarcinoma; nonmucinous
bronchioloalveolar carcinoma
Higher response rates in tumors with EGFR
mutations; negligible response rate in tumors with
KRAS mutations; intermediate effects in some
patients with other histologic types.
Pemetrexed Nonsquamous NSCLC Adenocarcinoma may be more susceptible because
of lower thymidylate synthase levels.
Bevacizumab Predominantly nonsquamous NSCLC Higher risk for fatal pulmonary hemorrhage with
squamous cell histology; risk may be lower with
small peripheral squamous tumors.
Cetuximab All Higher relative benefit observed in patients with
squamous histology.
Figitumumab (CP-751,871) Squamous NSCLC Phase III trial in combination with carboplatin and
paclitaxel was terminated in December 2009 due
to unanticipated toxicity and deaths.
Abbreviations: EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer.
4 Histology Mattersis becoming available for patients with advanced NSCLC
(Table 1). As part of the growing effort to individualize
therapy, histologic subtype must now be incorporated into
treatment decisions. It is essential to obtain an adequate
sample of tissue at the time of initial diagnosis for both his-
tologic confirmation and molecular testing, preferably via
surgical specimens, core biopsies, or serial fine-needle as-
piration samples. Adequate tissue availability may be the
key to identifying the most appropriate treatment for each
patient, improving the chances of finding an effective ther-
apy as early as possible in a patient’s treatment. It is likely
thatthedifferentialhistologicalresponsetonewertherapies
actually reflects underlying differences in the molecular
characteristics of the tumor. In fact, the lack of highly re-
producible inter-pathologist agreement in the identification
of squamous cell histology by HE slides alone [14] may
be improved by H  immunohistochemical staining for
molecular markers such as TTF1, TP63, and others to clas-
sify tumors that otherwise do not appear histologically dis-
tinct [15]. Eventually, specific molecular testing for
perturbations in genes like EGFR, KRAS, ALK, thymidy-
late synthase, and others will augment, and may even
supplant, the role of histology in predicting responses to
particular therapies.
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